Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease
Year: 2026
Type: article
Study design: Observational Study
Abstract: Minli Jiang,1,2,* Wei Li,1,* Lei Tian,3 Dong Xu,4 Yuanshuai Fan,5 Dong Liu,1 Yan He1 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2Department of Pharmacy, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, People’s Republic of China; 3Clinical Microbiology Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 4Department of Infection Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 5Department of Pharmacy, Pu’an Hospital of Traditional Chinese Medicine, Pu’an, 561500, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan He, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email [email protected] Dong Liu, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email [email protected]: The incidence of invasive fungal disease (IFD) has significantly increased in recent years, partly driven by the expanding immunocompromised population, as well as severe influenza and COVID-19. Amphotericin B (AmB) is highly effective against a broad spectrum of fungal infections and has a low drug resistance rate, but its clinical use is limited by toxicity. Amphotericin B colloidal dispersion (ABCD), a lipid formulation of AmB, is preferred in China for its reduced toxicity. This study assesses real-world clinical outcomes of ABCD as salvage therapy in IFD patients who failed prior treatment with triazoles or echinocandins.Methods: We conducted a single-center, retrospective study of IFD patients who received ABCD salvage therapy between September 2021 and February 2024. Clinical data were systematically reviewed to assess the clinical outcomes of ABCD.Results: Among the 60 patients included, the clinical response rate to ABCD was 71.7% (43/60; 95% confidence interval [CI], 59.2– 81.5%). Outcomes did not vary significantly with factors such as gender, underlying conditions, infection sites, or prior antifungal treatments. Incidence rates of hepatotoxicity, nephrotoxicity, and infusion-related reactions were 13.3%, 23.3%, and 1.7%, respectively. Five patients discontinued ABCD due to adverse events.Conclusion: In this real-world setting, ABCD salvage therapy was associated with favorable clinical outcomes and an acceptable safety profile in IFD patients who failed prior azole or echinocandin therapy.Keywords: amphotericin b colloidal dispersion, clinical response, invasive fungal infections, safety, salvage therapy
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7120777423
FWCI:
Cites:
Cited by:
Related to: